Clinical Trial Update: Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION) [Phase 4]

View source ↗

Summary

Phase 4 trial comparing prasugrel 5 mg versus ticagrelor 60 mg in patients with coronary artery disease; status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• prasugrel 5 mg (prasugrel)
• ticagrelor 60 mg (ticagrelor)

Snippet

Sponsor: Gyeongsang National University Hospital | Conditions: Coronary Artery Disease | Phase 4 | Status: UNKNOWN